JUST IN: Mindray Rumored To Go Private In PE Buyout
This article was originally published in PharmAsia News
China’s largest medical device maker, U.S.-listed Mindray, could be the latest healthcare company to delist and be taken private in a move to unlock value.
You may also be interested in...
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.
While new legislation has pushed prescription drug pricing high up the political agenda for US lawmakers, the issue has also come into the spotlight again for Chinese regulators, which have just launched new investigations into two officials. While the two countries are taking drastically different routes to tackling pricing, the developments show compliance risks remain high in China.
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.